
Integrating PROs into studies on MASH, also known as NASH, is crucial.

MASH is a debilitating chronic illness that significantly impairs patients' quality of life, affecting their daily routines, work, and mobility.

- Patient-centric appraisals are needed in the quest for treatments


Integrating PROs in MASH studies expands insights beyond MASH metrics, and helps understand MASH patients' concerns

At Kayentis, we have the full capability to run your MASH studies successfully:

- We have extensive experience in MASH and hepatic disorders research
 - We offer an enhanced patient-centric eCOA data entry
 - We are a key partner to biotech and big pharma companies

Learn more in the case study





[Download the case study](#)
[Contact us for more information](#)

Key Words:

- eCOA

- ePRO
- pediatric asthma
- clinical trial

[Learn more:](#)



Overcoming challenges in long-lasting pediatric clinical trials – Insights from site experts

26 March 2024

In this third episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)



Tackling the specificities of NASH/MASH clinical trials

26 March 2024

Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating

[Read More »](#)



Mastering pediatric asthma clinical trials

19 March 2024

Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of

[Read More »](#)



The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs

14 March 2024

NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally

[Read More »](#)



How DCTs Can Help Pediatric Clinical Research – Insights From Site Experts

12 March 2024

In this second episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)



Ophthalmology Clinical Trials

7 March 2024

Ophthalmic conditions and vision impairment currently affect 2.2 billion people globally. Data collection can be

[Read More »](#)